Where does Tarsus Pharmaceuticals, Inc.'s cash flow data come from?

Every line is extracted from Tarsus Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$48.27M+27.3%	-$66.42M+18.2%	-$81.16M+11.8%	-$91.99M+12.3%	-$104.94M+9.2%
Depreciation and amortization	$799K-2.8%	$822K+1.2%	$812K0.0%	$812K+14.0%	$712K+7.6%
Stock-based compensation	$46.76M+12.1%	$41.72M+19.9%	$34.81M+16.1%	$29.98M+2.6%	$29.23M+5.1%
Amortization of debt issuance costs	$613K+3.4%	$593K+3.1%	$575K+4.2%	$552K+8.9%	$507K+5.2%
Change in accounts receivable	——	——	——	——	——
Change in inventories	$1.9M+6.3%	$1.79M—	——	——	——
Change in accrued liabilities	——	——	——	——	——
Change in other assets	$511K-3.0%	$527K+261%	$146K+158%	-$252K+60.2%	-$633K-3.1%
Change in prepaid expenses	$20.25M+1,280%	-$1.72M-112%	$14.17M-39.2%	$23.3M+3,735%	-$641K-109%
Amortization of intangible assets	$881K0.0%	$881K+0.1%	$880K+12.8%	$780K+14.7%	$680K+25.9%
Change in receivables	——	——	——	——	——
Net cash from operating activities	——	——	——	-$80.87M-22.7%	-$65.89M+20.6%
Capital expenditures	$15.09M+53.0%	$9.86M+176%	$3.57M+83.7%	$1.95M-1.9%	$1.98M+26.5%
Purchases of investments	$394.42M+0.3%	$393.19M-12.2%	$447.57M+22.2%	$366.33M+29.1%	$283.65M+8.0%
Net cash from investing activities	——	——	-$150.96M-3.2%	-$146.22M-8.3%	-$135.04M+33.3%
Proceeds from issuance of common stock	——	——	——	——	——
Net cash from financing activities	$8.03M-94.4%	$143.39M-0.4%	$144M+1.4%	$142.08M-22.1%	$182.45M+18.0%
Net increase (decrease) in cash	——	——	——	——	-$15.36M+88.0%
Interest paid	$8.24M-1.3%	$8.34M-1.4%	$8.46M-19.4%	$10.49M+18.3%	$8.87M+15.7%
Income taxes paid	——	——	——	——	——
Accretion (Amortization) of Discounts and Premiums, Investments	$5.02M-8.5%	$5.48M-9.2%	$6.04M+6.9%	$5.65M+7.8%	$5.24M+24.3%
Non-cash interest expense	$613K+3.4%	$593K+3.1%	$575K+4.2%	$552K+8.9%	$507K+5.2%
Amortization of capitalized software and acquired intangible assets	$881K0.0%	$881K+0.1%	$880K+12.8%	$780K+14.7%	$680K+25.9%
Depreciation	$799K-2.8%	$822K+1.2%	$812K0.0%	$812K+14.0%	$712K+7.6%
Accrued compensation and employee benefits	——	——	——	——	——
Other current liabilities	——	——	——	——	——
Accrued liabilities	——	——	——	——	$38.51M+1.9%
Increase (Decrease) in Other Receivables	——	——	——	——	——
Increase (Decrease) in Prepaid Expense	$20.25M+1,280%	-$1.72M-112%	$14.17M-39.2%	$23.3M+3,735%	-$641K-109%
Non-cash lease expense	$595K-12.8%	$682K-2.7%	$701K+5.7%	$663K-0.6%	$667K+5.0%
Accrued payables for capital expenditures	$2.4M+57.0%	$1.53M-0.6%	$1.54M+250%	$440K+219%	$138K+39.4%
Offering costs included within accounts payable and other accrued liabilities	-$354K—	$0-100%	$3K—	——	——
Operating lease modification	——	$0-100%	$269.5K-50.0%	$539K-33.3%	$808.5K-25.0%
Income Taxes Paid, Net	——	——	——	——	——
Free cash flow	——	——	——	-$82.82M-22.0%	-$67.87M+19.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Tarsus Pharmaceuticals, Inc.'s cash flow data come from?: Every line is extracted from Tarsus Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.